Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab

Basit Öğe Kaydı
dc.authoridaksoy, asude/0000-0002-5609-9658
dc.authoridSumbul, Ahmet Taner/0000-0002-5573-906X
dc.authoridbenekli, mustafa/0000-0003-3184-4946
dc.authoridDEMIRCI, UMUT/0000-0002-4833-6721
dc.authoridoksuzoglu, berna/0000-0002-2756-8646
dc.authoridTanriverdi, Ozgur/0000-0002-0598-7284
dc.contributor.authorTonyali, Onder
dc.contributor.authorCoskun, Ugur
dc.contributor.authorYuksel, Sinemis
dc.contributor.authorInanc, Mevlude
dc.contributor.authorBal, Oznur
dc.contributor.authorAkman, Tulay
dc.contributor.authorYazilitas, Dogan
dc.date.accessioned2024-09-18T20:06:12Z
dc.date.available2024-09-18T20:06:12Z
dc.date.issued2016
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractPurpose: The aim of this study was to determine risk factors for brain metastasis as the first site of disease recurrence in patients with HER2-positive early-stage breast cancer (EBC) who received adjuvant trastuzumab. Methods: Medical records of 588 female patients who received 52-week adjuvant trastuzumab from 14 centers were evaluated. Cumulative incidence functions for brain metastasis as the first site of disease recurrence and the effect of covariates on brain metastasis were evaluated in a competing risk analysis and competing risks regression, respectively. Results: Median follow-up time was 36 months. Cumulative incidence of brain metastasis at 12 months and 24 months was 0.6% and 2%, respectively. HER2-enriched subtype (ER- and PR-) tumor (p = 0.001, RR: 3.4, 95% CI: 1.33-8.71) and stage 3 disease (p = 0.0032, RR: 9.39, 95% CI: 1.33-8.71) were significant risk factors for development of brain metastasis as the first site of recurrence. Conclusions: In patients with HER2 positive EBC who received adjuvant trastuzumab, HER2-enriched subtype (ER- and PR-) tumor and stage 3 disease were associated with increased risk of brain metastasis as the first site of disease recurrence. (C) 2015 Elsevier Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.breast.2015.11.006
dc.identifier.endpage26en_US
dc.identifier.issn0960-9776
dc.identifier.issn1532-3080
dc.identifier.pmid26801412en_US
dc.identifier.scopus2-s2.0-84959084796en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage22en_US
dc.identifier.urihttps://doi.org/10.1016/j.breast.2015.11.006
dc.identifier.urihttps://hdl.handle.net/20.500.12483/8363
dc.identifier.volume25en_US
dc.identifier.wosWOS:000368373500003en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherChurchill Livingstoneen_US
dc.relation.ispartofBreasten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBreast canceren_US
dc.subjectAdjuvant therapyen_US
dc.subjectTrastuzumaben_US
dc.subjectBrain metastasisen_US
dc.titleRisk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumaben_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
Tam Metin / Full text
Boyut:
322.76 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu